Conference Coverage

Bloating. Flatulence. Think SIBO


 

EXPERT ANALYSIS FROM RWCS 2018

Indeed, 40% of patients will experience recurrent SIBO symptoms within 9 months after a round of rifaximin. Recurrences are more common in patients on chronic proton pump–inhibitor therapy, the elderly, and those who have undergone appendectomy. Such patients may need another course of rifaximin once or twice per year.

“If they need rifaximin every 6 months, fine. Patients will be so grateful to you for that course of rifaximin,” Dr. Mahadevan said.

Patients with methane-predominant bacterial overgrowth, as opposed to hydrogen-predominant overgrowth, often benefit from concomitant neomycin at 500 mg twice per day along with their 10-14 days of rifaximin.

“A lot of our cirrhotic patients are on both,” she noted.

Pages

Recommended Reading

Opioid use higher in adults with health conditions
MDedge Rheumatology
Award for best hospital goes to … the Mayo Clinic
MDedge Rheumatology
FDA approves second adalimumab biosimilar for multiple conditions
MDedge Rheumatology
CREST syndrome and PBC are often associated
MDedge Rheumatology
PBC linked to increased risk of bone fracture
MDedge Rheumatology
Launch of adalimumab biosimilar Amjevita postponed
MDedge Rheumatology
PBC linked to low BMD, increased risk of osteoporosis
MDedge Rheumatology
Biosimilars poised to save $54 billion over the next decade
MDedge Rheumatology
FDA recommends voluntary recall of Limbrel
MDedge Rheumatology
FDA approves infliximab biosimilar Ixifi for all of Remicade’s indications
MDedge Rheumatology